Citations

Mayo Clinic

Showing 10 of 108551 citations.

Representations of an Ebola ‘outbreak’ through Story Technologies
Frankfurter, Raphael , Malik, Maya , Kpakiwa, Sahr David, McGinnis, Timothy, Malik, Momin M. , Chitre, Smit , Barrie, Mohamed Bailor , Dibba, Yusupha , Mulalu, Lulwama, Baldwinson, Raquel, Fallah, Mosoka , Rashid, Ismail, Richardson, Eugene T , Richardson, Eugene T , Malik, Momin , Kelly, John Daniel

BMJ Global Health | February 10, 2024 | Volume: 9 | Issue: 2 | Pages: e013210

10.1136/bmjgh-2023-013210 | PMID 38341190 Get It

Background Attempts to understand biosocial phenomena using scientific methods are often presented as value-neutral and objective; however, when used to reduce the complexity of open systems such as epidemics, these forms of inquiry necessarily entail normative considerations and are therefore fashioned by political worldviews (ideologies). From the standpoint of poststructural theory, the character of these representations is at most limited and partial. In addition, these modes of representation (as stories) do work (as technologies) in the service of, or in resistance to, power. Methods We focus on a single Ebola case cluster from the 2013–2016 outbreak in West Africa and examine how different disciplinary forms of knowledge production (including outbreak forecasting, active epidemiological surveillance, post-outbreak serosurveys, political economic analyses, and ethnography) function as Story Technologies. We then explore how these technologies are used to curate ‘data,’ analysing the erasures, values, and imperatives evoked by each. Results We call attention to the instrumental—in addition to the descriptive—role Story Technologies play in ordering contingencies and establishing relationships in the wake of health crises. Discussion By connecting each type of knowledge production with the systems of power it reinforces or disrupts, we illustrate how Story Technologies do ideological work. These findings encourage research from pluriversal perspectives and advocacy for measures that promote more inclusive modes of knowledge production.
Graduate training, credentialing, and continuing education to prepare genetic counselors for laboratory roles—Results of a national survey
Schwartz, Lisa , Mackall, Mia S. , Arjunan, Aishwarya , Goodenberger, McKinsey L. , Mills, Rachel , Ham, C. , Witherington, Sarah , Goodenberger, McKinsey , Ham, Chloe , Arjunan, Aishwarya , Witherington, Sarah , Mills, Rachel

Journal of Genetic Counseling | February 10, 2024 | Volume: 34 | Issue: 1 | Pages: No page available

10.1002/jgc4.1883 | PMID 38339832 Get It

Abstract Opportunities for genetic counselors to work in a variety of practice settings have greatly expanded, particularly in the laboratory. This study aimed to assess attitudes of genetic counselors working both within and outside of the laboratory setting regarding (1) the re‐wording and/or expansion of key measures of genetic counselors' competency, including practice‐based competencies (PBCs) and board examination, to include laboratory roles, (2) preparation and transferability of competencies developed in master's in genetic counseling (MGC) programs to different roles, (3) need of additional training for genetic counselors to practice in laboratory settings, and (4) preferred methods to obtain that training. An e‐blast was sent to ABGC diplomats ( N = 5458) with a link to a 29‐item survey with 12 demographic questions to compare respondents to 2021 NSGC Professional Status Survey (PSS) respondents. Statistical comparisons were made between respondents working in the laboratory versus other settings. Among 399 responses received, there was an oversampling of respondents working in the laboratory (52% vs. 20% in PSS) and in non‐direct patient care positions (47% vs. 25% in PSS). Most respondents agreed the PBCs were transferable to their work yet favored making the PBCs less direct patient care‐focused, expanding PBCs to align with laboratory roles, adding laboratory‐focused questions to the ABGC exam, and adding laboratory‐focused training in MGC programs. Most agreed requiring post‐MGC training would limit genetic counselors' ability to change jobs. Genetic counselors working in the laboratory reported being significantly less prepared by their MGC program for some roles ( p < 0.001) or how the PBCs applied to non‐direct patient care positions ( p < 0.001). Only 53% of all respondents agreed that NSGC supports their professional needs and others in their practice area, and genetic counselors working in the laboratory were significantly less likely to agree ( p = 0.002). These sentiments should be further explored.
Renal cortical necrosis – a rare manifestation of dengue fever: A case report
Rehman, Fazal ur, Rehan, Syeda Tayyaba , Yousaf, Fatima, Rathore, Navin, Rind, Bakhtawar Jamal, Eljack, Mohammed Mahmmoud Fadelallah , Asghar, Muhammad Sohaib , Omair, Farruk, Mahmmoud Fadelallah Eljack, Mohammed , Asghar, Muhammad S , Rehman, Fazal ur, Omair, Farruk

Medicine | February 9, 2024 | Volume: 102 | Issue: 43 | Pages: e35719

10.1097/md.0000000000035719 | PMID 37904359 Get It

Rationale: Dengue fever is a widespread mosquito-borne viral disease, most prevalent in the tropical and subtropical areas of the world. There has been a significant rise in the incidence and number of outbreaks of dengue in recent years, which has made it a matter of global concern. It may be associated with a number of renal complications, ranging from hematuria, proteinuria, glomerulonephritis, and acute tubular necrosis. However, renal cortical necrosis (RCN) is a rare renal complication of this disease. Patients concerns: We report the case of a young gentleman who presented with fever, vomiting, and anuria. On workup, he was found to be having complicated Dengue fever with RCN resulting in acute renal failure. Diagnosis: To the best of our knowledge, RCN is not a reported renal complication of dengue fever. Interventions and outcomes: Our report highlights the importance of early consideration of renal cortical necrosis in patients with dengue fever and persistent anuria. Lesson: This would allow for better disease prognostication while enabling physicians to develop more effective treatment strategies.
Comparative Analysis of US Guidelines for the Management of Cutaneous Squamous Cell and Basal Cell Carcinoma
Mittal, Bharat B. , Mittal, Amit, Mittal, Bharat B , Mittal, Amit

Journal of Skin Cancer | February 9, 2024 | Volume: 2024 | Issue: No issue available | Pages: 1-12

10.1155/2024/3859066 | PMID 38370137 Get It

Background. This study presents a comparative analysis of recently published guidelines to manage cutaneous squamous cell carcinoma (cSCC) and cutaneous basal cell carcinoma (cBCC) within the United States (US). Methods. A PubMed database search was performed for the time period between June 1, 2016, and December 1, 2022. A comprehensive comparison was performed in the following clinical interest areas: staging and risk stratification, management of primary tumor and regional nodes with curative intent, and palliative treatment. Results. Guidelines from 3 organizations were analyzed: the American Academy of Dermatology (AAD), the National Comprehensive Cancer Network (NCCN), and the American Society for Radiation Oncology (ASTRO). The guidelines used different methodologies to grade evidence, making comparison difficult. There was agreement that surgery is the preferred treatment for curative cBCC and cSCC. For patients ineligible for surgery, there was a consensus to recommend definitive radiation. AAD and NCCN recommended consideration of other topical modalities in selected low-risk cBCC. Postoperative radiation therapy (PORT) was uniformly recommended in patients with positive margins that could not be cleared with surgery and in patients with nerve invasion. The definition and extent of nerve invasion varied. All guidelines recommended surgery as the primary treatment in patients with lymph node metastases in a curative setting. The criteria used for PORT varied; NCCN and ASTRO used lymph node size, number of nodes, and extracapsular extension for recommending PORT. Both NCCN and ASTRO recommend consideration of systemic treatment along with PORT in patients with extracapsular extension. Conclusion: US guidelines provide contemporary and complementary information on the management of cBCC and cSCC. There are opportunities for research, particularly in the areas of staging, indications for adjuvant treatment in curative settings, extent of nerve invasion and prognosis, and the role of systemic treatments in curative and palliative settings.
Core outcomes in nerve surgery: development of a core outcome set for brachial plexus and upper extremity nerve injuries
Wilson, Thomas J. , Ali, Zarina S. , Davis, Gavin A , Desai, Ketan, Garozzo, Debora, Guedes, Fernando , Jack, Megan M. , Jacques, Line , Kretschmer, Thomas , Midha, Rajiv, Puffer, Ross C. , Rasulić, Lukas , Ray, Wilson Z. , Rizk, Elias , Rodríguez-Aceves, Carlos Alberto , Shapira, Yuval, Spinner, Robert J. , Zager, Eric L. , Davis, Gavin A. , Dengler, Nora F. , Mahan, Mark A , Pondaag, Willem , Smith, Brandon W. , Socolovsky, Mariano

Journal of Neurosurgery | February 9, 2024 | Volume: 141 | Issue: 2 | Pages: 474-483

10.3171/2023.11.jns232272 | PMID 38335525 Get It

OBJECTIVE When considering traumatic brachial plexus and upper extremity nerve injuries, iatrogenic nerve injuries, and nontraumatic nerve injuries, brachial plexus and upper extremity nerve injuries are commonly encountered in clinical practice. Despite this, data synthesis and comparison of available studies are difficult. This is at least in part due to the lack of standardization in reporting and a lack of a core outcome set (COS). Thus, there is a need for a COS for adult brachial plexus and upper extremity nerve injuries (COS-BPUE). The objective of this study was to develop a COS-BPUE using a modified Delphi approach. METHODS A 5-stage approach was used to develop the COS-BPUE: 1) consortium development, 2) literature review to identify potential outcome measures, 3) Delphi survey to develop consensus on outcomes for inclusion, 4) Delphi survey to develop definitions, and 5) consensus meeting to finalize the COS and definitions. The study followed the Core Outcome Set-STAndards for Development (COS-STAD) recommendations. RESULTS The Core Outcomes in Nerve Surgery (COINS) Consortium comprised 23 participants, all neurological surgeons, representing 13 countries. The final COS-BPUE consisted of 36 data points/outcomes covering demographic, diagnostic, patient-reported outcome, motor/sensory outcome, and complication domains. Appropriate instruments, methods of testing, and definitions were set. The consensus minimum duration of follow-up was 24 months, with the consensus optimal time points for assessment being preoperatively and 3, 6, 12, and 24 months postoperatively. CONCLUSIONS The COINS Consortium developed a consensus COS and provided definitions, methods of implementation, and time points for assessment. The COS-BPUE should serve as a minimum set of data that should be collected in all future neurosurgical studies on adult brachial plexus and upper extremity nerve injuries. Incorporation of this COS should help improve consistency in reporting, data synthesis, and comparability, and should minimize outcome reporting bias.
How a Fish Can “See” with its Skin
Carmichael, Stephen W.

Microscopy Today | February 9, 2024 | Volume: 32 | Issue: 1 | Pages: 8-9

10.1093/mictod/qaad101 Get It

The Duration and Intensity of High Frequency Alternating Current Influences the Degree and Recovery of Nerve Conduction Block
Waataja, Jonathan J. , Honda, Christopher N., Anders, Jennifer , Nihilani, Raj K., Farajidavar, Aydin , Asp, Anders J

IEEE Transactions on Biomedical Engineering | February 9, 2024 | Volume: 71 | Issue: 7 | Pages: 2170-2179

10.1109/tbme.2024.3364350 | PMID 38335073 Get It

Room for Improvement: The Impact of Guideline-Recommended Extended Thromboprophylaxis in Patients Undergoing Abdominal Surgery for Colorectal and Anal Cancer at a Tertiary Referral Center
Broccard, Sacha P. , Brennan, Emily , Spaulding, Aaron , DeLeon, Michelle , Mishra, Nitin , Casler, John D., Colibaseanu, Dorin , Edwards, Michael A. , Brennan, Emily R, Spaulding, Aaron C. , DeLeon, Michelle F, Colibaseanu, Dorin T , Spaulding, Aaron

Diseases of the Colon & Rectum | February 9, 2024 | Volume: 67 | Issue: 5 | Pages: 714-722

10.1097/dcr.0000000000003158 | PMID 38335005 Get It

BACKGROUND: Venous thromboembolism occurs in approximately 2% of patients undergoing abdominal and pelvic surgery for cancers of the colon, rectum, and anus and is considered preventable. The American Society of Colon and Rectal Surgeons recommends extended prophylaxis in high-risk patients, but there is low adherence to the guidelines. OBJECTIVE: This study aims to analyze the impact of venous thromboembolism risk-guided prophylaxis in patients undergoing elective abdominal and pelvic surgeries for colorectal and anal cancers from 2016 to 2021. DESIGN: This was a retrospective analysis. SETTING: The study was conducted at a multisite tertiary referral academic health care system. PATIENTS: Patients who underwent elective abdominal or pelvic surgery for colon, rectal, or anal cancer. MAIN OUTCOME MEASURES: Receipt of Caprini-guided venous thromboembolism prophylaxis, 90-day postoperative rate of deep vein thrombosis, pulmonary embolism, venous thromboembolism, and bleeding events. RESULTS: A total of 3504 patients underwent elective operations, of whom 2224 (63%) received appropriate thromboprophylaxis in the inpatient setting. In the postdischarged cohort of 2769 patients, only 2% received appropriate thromboprophylaxis and no thromboembolic events were observed. In the group receiving inappropriate thromboprophylaxis, at 90 days postdischarge, the deep vein thrombosis, pulmonary embolism, and venous thromboembolism rates were 0.60%, 0.40%, and 0.88%, respectively. Postoperative bleeding was not different between the 2 groups. LIMITATIONS: Limitations to our study include its retrospective nature, use of aggregated electronic medical records, and single health care system experience. CONCLUSION: Most patients in our health care system undergoing abdominal or pelvic surgery for cancers of the colon, rectum, and anus were discharged without appropriate Caprini-guided venous thromboembolism prophylaxis. Risk-guided prophylaxis was associated with decreased rates of inhospital and postdischarge venous thromboembolism without increased bleeding complications. See Video Abstract. MARGEN DE MEJORA: EL IMPACTO DE LA TROMBOPROFILAXIS RECOMENDADA POR LAS DIRECTRICES EN PACIENTES SOMETIDOS A CIRUGÍA ABDOMINAL POR CÁNCER COLORRECTAL Y ANAL EN UN CENTRO DE REFERENCIA TERCIARIO ANTECEDENTES: El tromboembolismo venoso ocurre en aproximadamente el 2% de los pacientes sometidos a cirugía abdominal y pélvica por cánceres de colon, recto y ano, y se considera prevenible. La Sociedad Estadounidense de Cirujanos de Colon y Recto recomienda una profilaxis prolongada en pacientes de alto riesgo, pero el cumplimiento de las directrices es bajo. OBJETIVO: Este estudio tiene como objetivo analizar el impacto de la profilaxis guiada por el riesgo de tromboembolismo venoso (TEV) en pacientes sometidos a cirugías abdominales y pélvicas electivas por cáncer colorrectal y anal entre 2016 y 2021. DISEÑO: Este fue un análisis retrospectivo. AJUSTE: El estudio se llevó a cabo en un sistema de salud académico de referencia terciaria de múltiples sitios. PACIENTES: Pacientes sometidos a cirugía abdominal o pélvica electiva por cáncer de colon, recto o ano. PRINCIPALES MEDIDAS DE RESULTADO: Recepción de profilaxis de tromboembolismo venoso guiada por Caprini, tasa postoperatoria de 90 días de trombosis venosa profunda, embolia pulmonar, tromboembolismo venoso y eventos de sangrado. RESULTADOS: Un total de 3.504 pacientes se sometieron a operaciones electivas, de los cuales 2.224 (63%) recibieron tromboprofilaxis adecuada en el ámbito hospitalario. En el cohorte de 2.769 pacientes después del alta, solo el 2% recibió tromboprofilaxis adecuada en la que no se observaron eventos tromboembólicos. En el grupo que recibió tromboprofilaxis inadecuada, a los 90 días después del alta, las tasas de trombosis venosa profunda, embolia pulmonar y tromboembolia venosa fueron del 0,60%, 0,40% y 0,88%, respectivamente. El sangrado posoperatorio no fue diferente entre los dos grupos. LIMITACIONES: Las limitaciones de nuestro estudio incluyen su naturaleza retrospectiva, el uso de registros médicos electrónicos agregados y la experiencia de un solo sistema de atención médica. CONCLUSIÓN: La mayoría de los pacientes en nuestro sistema de salud sometidos a cirugía abdominal o pélvica por cánceres de colon, recto y ano fueron dados de alta sin una profilaxis adecuada de TEV guiada por Caprini. La profilaxis guiada por el riesgo se asoció con menores tasas de tromboembolismo venoso hospitalario y dado de alta sin un aumento de las complicaciones de sangrado. (Traducción—Dr. Aurian Garcia Gonzalez)
Leadless pacemakers at 5-year follow-up: the Micra transcatheter pacing system post-approval registry
Garweg, Christophe , Clementy, Nicolas, Al-Samadi, Faisal, Iacopino, Saverio , Roberts, Paul R. , Johansen, Jens Brock , Vinolas-Prat, X., Cha, Yong‐Mei , Grubman, Eric , Bordachar, Pierre , Fagan, Dedra H. , Piccini, Jonathan P. , El-Chami, Mikhael F , Garweg, Christophe , Johansen, Jens Brock , Cha, Yong-Mei , Stromberg, Kurt , El‐Chami, Mikhael F. , Clémenty, Nicolas , Martínez‐Sande, José Luis , Tondo, Claudio , Stromberg, Kurt

European Heart Journal | February 9, 2024 | Volume: 45 | Issue: 14 | Pages: 1241-1251

10.1093/eurheartj/ehae101 | PMID 38426911 Get It

Abstract Background and Aims Prior reports have demonstrated a favourable safety and efficacy profile of the Micra leadless pacemaker over mid-term follow-up; however, long-term outcomes in real-world clinical practice remain unknown. Updated performance of the Micra VR leadless pacemaker through five years from the worldwide post-approval registry (PAR) was assessed. Methods All Micra PAR patients undergoing implant attempts were included. Endpoints included system- or procedure-related major complications and system revision rate for any cause through 60 months post-implant. Rates were compared through 36 months post-implant to a reference dataset of 2667 transvenous pacemaker patients using Fine–Gray competing risk models. Results 1809 patients were enrolled between July 2015 and March 2018 and underwent implant attempts from 179 centres in 23 countries with a median follow-up period of 51.1 months (IQR: 21.6–64.2). The major complication rate at 60 months was 4.5% [95% confidence interval (CI): 3.6%–5.5%] and was 4.1% at 36 months, which was significantly lower than the 8.5% rate observed for transvenous systems (HR: .47, 95% CI: .36–.61; P &lt; .001). The all-cause system revision rate at 60 months was 4.9% (95% CI: 3.9%–6.1%). System revisions among Micra patients were mostly for device upgrades (41.2%) or elevated thresholds (30.6%). There were no Micra removals due to infection noted over the duration of follow-up. At 36 months, the system revision rate was significantly lower with Micra vs. transvenous systems (3.2% vs. 6.6%, P &lt; .001). Conclusions Long-term outcomes with the Micra leadless pacemaker continue to demonstrate low rates of major complications and system revisions and an extremely low incidence of infection.
Brepocitinib, Zimlovisertib, and Ropsacitinib in Hidradenitis Suppurativa
Peeva, Elena , Forman, Seth , Moiin, Ali, Khattri, Saakshi , Mangold, Aaron R. , Ghosh, Pranab , Banfield, Christopher , Mangold, A R , Kimball, Alexa B. , Porter, Martina Lee , Oemar, Barry S.

NEJM Evidence | February 9, 2024 | Volume: 3 | Issue: 3 | Pages: No page available

10.1056/evidoa2300155 | PMID 38335032 Get It